My ePortfolio Register   

Targeting tumour vasculature by DNA vaccines

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.04.16
Views: 1214
Rating:

Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA

Dr Facciabene (University of Pennsylvania, Philadelphia, USA) talks to ecancertv at ITOC3 about novel TEM-1 vaccines.

The vaccine targets Tumour Endothelial Marker 1, eliminating tumour vasculature and inducing a secondary immune response.

The trials have proven effective in models of breast cancer, Lewis lung carcinoma, cervical cancer and colorectal cancer.

Host angiogenesis in wound healing and pregnancy is unaffected by the vaccine.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence